The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Precision medicine for lung cancer decision-making: Evaluation of an -omics based FFT approach to personalized medicine.
 
Isa Mambetsariev
No Relationships to Disclose
 
Benjamin Djulbegovic
Research Funding - GlaxoSmithKline (Inst)
 
Rebecca Pharaon
No Relationships to Disclose
 
Blake Hewelt
No Relationships to Disclose
 
Erminia Massarelli
Consulting or Advisory Role - Genentech/Roche
Speakers' Bureau - AstraZeneca; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Tessa Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
 
Marianna Koczywas
Speakers' Bureau - AstraZeneca
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Euclises; Exelixis; Guardant Health; Loxo; Precision Health Economics; Seagen; Takeda; Tesaro
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ARIAD (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Loxo (Inst); Molecular Partners (Inst); Pfizer (Inst); Seagen (Inst); Xcovery (Inst); Zeno Pharmaceuticals (Inst)
 
Ravi Salgia
No Relationships to Disclose